2018ASH静脉血栓栓塞管理指南：肝素诱导的血小板减少症.pdf

CLINICAL GUIDELINES American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia Adam Cuker,1,2 Gowthami M. Arepally,3 Beng H. Chong,4 Douglas B. Cines,1,2 Andreas Greinacher,5 Yves Gruel,6 Lori A. Linkins,7 Stephen B. Rodner,8 Sixten Selleng,9 Theodore E. Warkentin,7,10 Ashleigh Wex,11 Reem A. Mustafa,12,13 Rebecca L. Morgan,12 and Nancy Santesso12 1Department of Medicine and 2Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3Department of Medicine, Duke University Medical Center, Durham, NC; 4Department of Haematology, University of New South Wales, Sydney, NSW, Australia; 5Institute of Immunology and Transfusion Medicine, University of Greifswald, Greifswald, Germany; 6Department of Haematology-Haemostasis, Trousseau Hospital, Tours, France; 7Department of Medicine, McMaster University, Hamilton, ON, Canada; 8New York, NY; 9Department of Anaesthesiology, University of Greifswald, Greifswald, Germany; 10Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; 11Columbus, OH; 12Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; and 13Department of Medicine, University of Missouri–Kansas City, Kansas City, MO Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended